Manitoba
Health, Seniors and Long-Term Care

Information for Pharmacists

Claims Submission Procedure – COVID-19 Oral Antiviral Drugs

Effective May 20, 2022
Updated March 26, 2024

Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.

- This Claims Submission Procedure (CSP) applies to community pharmacy dispensation of federally procured COVID-19 oral antiviral drugs to any person in Manitoba with a valid prescription. This is not limited to residents of Manitoba. A Manitoba Health Registration card is not required for coverage.

- COVID-19 oral antiviral drug(s) include:
  - Paxlovid (nirmatrelvir and ritonavir) – Drug Identification Number 02524031
  - Paxlovid (nirmatrelvir and ritonavir) for moderate renal impairment – Drug Identification Number 02527804

- Paxlovid is also now available to order commercially in Manitoba.
  - Commercially procured Paxlovid is not currently a benefit under Manitoba's provincial drug plans (e.g., Pharmacare).
  - Claims for commercially procured product will not be reimbursed.
  - If a pharmacy is found on audit to have submitted commercially procured Paxlovid claims for fiscal adjudication recovery of fees will occur.

- Pharmacies should continue to dispense federally procured Paxlovid to clients at no cost rather provide commercially procured Paxlovid whenever possible. This should include directing clients to other pharmacies with remaining federally procured stock, when a pharmacy has no more on hand.

- When dispensing federally procured Paxlovid:
  - Clients presenting with a prescription must not be charged any out-of-pocket costs and even if the client is enrolled in Pharmacare or another provincial or federal drug program (e.g., Family Services/EIA); there is no requirement to meet a deductible or co-pay.
  - A professional fee of $15 or the pharmacy's Usual and Customary Fee, whichever is lower, will be reimbursed to pharmacies per treatment course dispensed. The professional fee includes any associated delivery fees. For added clarity, pharmacies may not charge any additional fees for this product or associated services.

- Manitoba is outlining the following product selection tree:
  1. Pharmacy providers should dispense Paxlovid packages in alignment with the prescribed treatment course (i.e., full dose or renal impairment dosing), if the pharmacy has inventory on hand.
  2. If the pharmacy does not have the appropriate package size on hand, then packaging should be adjusted as outlined below.*
  3. If the pharmacy does not have federally procured Paxlovid on hand, clients should be directed to other pharmacies with remaining federally procured stock.

* Pharmacies dispensing two (2) renal impairment dose packages (DIN: 02527804) to patients prescribed the full dose may claim only one (1) Professional Fee for the dispensation (i.e., as only one prescription is being dispensed).

Dispensing Instructions to Manage Supply:

To extend the available federal supply, pharmacists should adjust tablets, instructions and client counselling as necessary when dispensing Paxlovid.

The Health Canada approved dosage of Paxlovid is as follows:

- **Patients requiring the full dose (i.e., not requiring a renal impairment dose adjustment):** 300 mg nirmatrelvir (two 150 mg pink tablets) and 100 mg ritonavir (one 100 mg white tablet) twice daily for 5 days. All three tablets are taken together per dose.

- **Patients requiring the renal impairment dose adjustment:** 150 mg of nirmatrelvir (one 150 mg pink tablet) and 100 mg ritonavir (one 100 mg white tablet) twice daily for 5 days. Two tablets are taken together per dose.

To use full dose packaging (DIN: 02524031) for patients requiring the renal impairment dose adjustment:

- Remove 1 nirmatrelvir 150 mg (pink tablet) from both the morning and evening dose of each daily card and discard the extra nirmatrelvir tablets.

To use renal impairment dose packaging (DIN: 02527804) for patients requiring the full dose:

- Dispense 2 renal impairment dose packages. From 1 package, remove 1 ritonavir 100 mg (white tablet) from both the morning and evening dose of each daily card and discard the extra ritonavir tablets.

Disposal of expired product:

Once federally procured Paxlovid on hand at the pharmacy level has expired according to the extended expiry date, please:

- Dispose of expired product according to standard pharmacy process. Do not return expired product to the distributor.
- Provide notification of any such disposal of expired product to Manitoba Health, by completing and returning the following table to PDPInfoAudit@gov.mb.ca

Pharmacy Name:	
Pharmacy Provider Number: P	
Lot Number	**Quantity Disposed of (i.e., number of treatment courses)**

Submission Procedure for Manitobans WITH a Personal Health Identification Number (PHIN):

- Submit claim to DPIN for **fiscal** adjudication under the Carrier Code applicable to the client. You must receive a 'D1, DIN not a benefit' message back from DPIN in order to ensure payment.
    - Indicate the quantity of each Paxlovid pre-packaged treatment course dispensed as:
        - 30 for full treatment course dispensed (for DIN 02524031, or the adjustment of two packages of DIN 02527804 for clients requiring full dose Paxlovid)
        - 20 for moderate renal impairment dosing treatment course dispensed (for DIN 02527804, or if this product is unavailable for DIN 02524031)
    - Indicate the total days' supply of Paxlovid as five (5);
    - Enter an ingredient cost of $0.00; and
    - Enter a Professional Fee as per approval letter from MH in response to EOI for COVID-19 Oral Antiviral Drug Provision
    - **Claim will be rejected and DPIN will return a 'D1, DIN not a benefit' message**

Submission Procedure for Manitobans WITHOUT a Personal Health Identification Number:

- Complete a 'COVID-19 ORAL Antiviral Drug Claim Form – Client without a Manitoba Health PHIN' and submit to DPIN via fax within 28 days of dispensation.

If the client has a PHIN, the claim MUST be entered into DPIN.

- Failure to submit the claim according to one of the procedures above will result in no reimbursement to the pharmacy for the allowable professional fee.
- **Pharmacy will NOT see the professional fee paid to them at time of on-line claim submission.**
- **Professional fees for COVID-19 oral antiviral drug claims will be tracked and reimbursed via electronic funds transfer once a month. Reimbursement will appear on corresponding pharmacy statement as positive adjustments. One adjustment per claim.**
- If a claim is submitted and not dispensed to patient, the pharmacy must reverse the claim on-line within 28 days of claim date.
- If a claim is submitted, and not dispensed to patient, and not reversed within 28 days, the pharmacy must submit a reversal/adjustment form.
- Pharmacy can submit an adjustment for claim not submitted on-line within seven (7) days of dispensing. DPIN team will review for possible reimbursement.

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs posted at:
https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html

Please send an e-mail to PDPInfoAudit@gov.mb.ca.